NCT01928888View on ClinicalTrials.gov

Placebo Controlled Phase IV Study to Compare the Efficacy and Safety of a Single Dose of Oral Talcid, a Single Dose of Oral Famotidine and a Single Dose of Placebo in Patients With Acute Heartburn Episodes

PHASE4CompletedINTERVENTIONAL
Enrollment

559

Participants

Timeline

Start Date

May 31, 2003

Primary Completion Date

February 29, 2004

Study Completion Date

February 29, 2004

Conditions
Heartburn
Interventions
DRUG

Talcid (Hydrotalcite, BAY4516H)

2 tablets hydrotalcite (2x500mg) 1000mg and 1 capsule placebo to famotidine

DRUG

Famotidine

2 tablets placebo to hydrotalcite and 1 capsule famotidine 10 mg

DRUG

Placebo

2 tablets placebo to hydrotalcite and 1 capsule placebo to famotidine

Trial Locations (5)

10437

Berlin

60596

Frankfurt am Main

01307

Dresden

04107

Leipzig

Unknown

Ask Central Contact

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT01928888 - Placebo Controlled Phase IV Study to Compare the Efficacy and Safety of a Single Dose of Oral Talcid, a Single Dose of Oral Famotidine and a Single Dose of Placebo in Patients With Acute Heartburn Episodes | Biotech Hunter | Biotech Hunter